GENEART AG Publishes Preliminary Figures for Q3 2008

- Net sales for 2008 at EUR 11.7M after 9 months
- EBIT reaches EUR 1.4M
- For the entire year of 2008, net sales between EUR 15.5M and 16.5M
are expected with EBIT at prior year's level
- Market position was further expanded in slightly weaker market
conditions

Regensburg, November 6, 2008 - GENEART AG, the global leader in gene
synthesis and specialist in the field of Synthetic Biology, reached
net sales of EUR 11.7M (preliminary figures) during the first nine
months of 2008. This exceeds prior year's net sales figures of EUR
9.0M for the reference period by 30 %. The operating result (EBIT)
totaled EUR 1.4M after nine months and was therefore at previous
year's levels.

The results of the third quarter with net sales of EUR 3.9M (Q3 2007:
EUR 3.5M) and EBIT of EUR 0.5M (Q3 2007: EUR 0.7M) were largely
affected by the current market insecurity. While GENEART's figures
for the first half of 2008 reflected budgeted numbers precisely, the
annual net sales prognosis needs to be adjusted to between EUR 15.5M
and 16.5M (net sales 2007: EUR 12.3M) due to current market
developments. EBIT is expected to reach previous year's levels of
approx. EUR 1.8M.

Strong growth of small and medium-sized orders during the third
quarter completely offset reduced orders on hand due to expiring
large volume orders. This enabled GENEART to strengthen its position
versus its competition during difficult market conditions. A
regionally diversified customer structure across various industries
contributed to this positive development, which cushions fluctuations
of individual market segments as much as possible. With this in mind
the company expects steady, but slightly reduced growth for 2009.

"Over the past months we managed again to significantly improve our
market position and customer base and hence lastingly reduced the
dependency on major contracts, which materialize only haltingly in
the current market", commented Christian Ehl, CEO of GENEART.

"Our investments of EUR 3.8M during the first nine months of 2008 are
an indication of our undaunted trust in a positive market development
over the medium term. At the same time we increased our competitive
advantage as a technology and cost leader in the field of gene
synthesis by industrializing and automating our technology. These
competitive advantages are a vital requirement to consistently expand
our market share in the future", added Prof. Dr. Ralf Wagner, CEO of
GENEART.

For further inquiries, please contact:

Bernd Merkl
GENEART AG
Josef-Engert-Str. 11
93053 Regensburg
Germany
Phone: +49-(0)941-942 76-638
Fax: +49-(0)941-942 76-711
ir@geneart.com
www.geneart.com

Frank Ostermair
Better Orange IR & HV AG
Haidelweg 48
81241 Munich
Germany
Phone: +49-(0)89-8896906-10
Fax: +49-(0)89-8896906-66
info@better-orange.de
www.better-orange.de

Legal Information
This document may contain estimates, prognoses and opinions about
company plans and objectives, products or services, future results,
opinions about these results or opinions leading up to these results.
All these projections into the future are subject to risk,
uncertainty and unforeseeable change outside the control of the
GENEART Group. Many factors may lead to actual results, which
considerably deviate from the given projections for these results.

About GENEART AG:
In 2000, GENEART entered the gene synthesis market and has since
become the global market leader. Today, the company is one of the
leading specialists in the Synthetic Biology field. Experts at
GENEART provide key technologies for the development and production
of new therapeutics and vaccines. Customers also take advantage of
GENEART services to customize enzyme attributes, such as the
attributes of enzymes used as detergent additives, and to construct
bacteria, which produce complex biopolymers or break down polymers,
such as synthetics, petroleum components, etc. Our production and
service spectrum spans a wide range, from the production of synthetic
genes according to DIN EN ISO 9001-2000, to the creation of gene
libraries in the combinatorial biology, to the development and
production of DNA-based biologically active substances. The GENEART
AG in Regensburg (Germany) and the subsidiaries GENEART Inc. in
Toronto (Canada) and GENEART Inc. in San Francisco (USA) employ more
than 190 people. Since May 2006, GENEART is listed on the German
Stock Exchange.

This announcement was originally distributed by Hugin. The issuer is
solely responsible for the content of this announcement.
Copyright © Hugin AS 2008. All rights reserved.